The combination therapy of SAHA (40 mg/kg, intraperitoneal injection every 3 days) and B7x neutralizing antibody (200 μg/mouse, intraperitoneal injection every 2 days) significantly delayed tumor growth, with a tumor inhibition rate of 80.6%, and significantly increased the infiltration of CD8+ and CD4+ T cells in the tumor microenvironment (67). The gene discussed is VTCN1; the disease is neoplasm.